The Relationship of Lipo (a) and Paraoxonase with Diabetes Mellitus

Yıl 2019, Cilt: 1 Sayı: 2, 5 - 8, 31.07.2019

Güler Kuşçu Günay , Tuğba Atov Bayrak , Mehmet Özdin

Öz

The aim of this review is to examine
the relationship between diabetes mellitus and lipoprotein a (lipo a) and
Paraoxonase-1 (PON1). For this, the original publications of the last decade
have been scanned. Findings showed that; lipo (a) is associated with many
chronic and high-mortality diseases. In the studies lipo (a) elevated diseases;
myocardial infarction, chronic renal failure, lung cancer, stroke, diabetes
mellitus (DM) and diabetic nephropathy. On the other hand, the level of lipoa
(a) was found to be decreased in patients with liver cirrhosis. According to
the data of these studies, extensive systemic involvement of DM was found to be
effective on the level of lipo (a). A similar situation was found between DM
and PON1. In addition, PON1 studies were performed with high density
lipoprotein (HDL). In all of these studies, it was found that PON1 levels
decreased with HDL. As a result many studies conducted in recent years show
that; PON1 levels of patients with diabetes mellitus decrease, while lipo (a) levels
are increased.

Anahtar Kelimeler

PON-1, lipo(a), diabetes mellitus

Lipo(a) ve Paraoksonazın Diabetes Mellitus ile İlişkisi

Öz

Bu derlemenin amacı, diabetes
mellitus ile Lipoprotein a (lipo a) ve Paraoksonaz-1 (PON1) arasındaki ilişkiyi
incelemektir. Bunun için, son on yıldaki orijinal yayınlar taranmıştır. Elde
edilen bulgular göstermiştir ki; lipo (a),  birçok kronik ve yüksek mortaliteli hastalıkla
ilişkilidir. Araştırmalarda lipo (a) seviyesi yüksek çıkan hastalıklar;
miyokard enfarktüsü, kronik böbrek yetmezliği, akciğer kanseri, inme, diabetes mellitus
(DM) ve diyabetik nefropati olarak tespit edilmiştir. Öte yandan, karaciğer
sirozu olan hastalarda lipoa (a) seviyesinin azalmış olduğu görüldü. Yine bu
araştırmaların verilerine göre, DM’ün geniş sistemik tutulumunun lipo (a)
seviyesindeki yüksekliğe etkili olduğu görülmüştür. Benzer durum DM ve PON1 düşüklüğü arasında da tespit
edilmiştir. İlave olarak, PON1 araştırmalarının, yüksek yoğunluklu
lipoproteinin (HDL) ile birlikte yapıldığı görülmüştür. Tüm bu çalışmalarda, PON1
seviyelerinin HDL ile birlikte azaldığı tespit edilmiştir. Sonuç olarak, son
yıllarda yapılan pek çok araştırma göstermektedir ki; diabetes mellituslu
hastaların PON1 seviyeleri azalırken, lipo (a) seviyeleri yükselmektedir.

Anahtar Kelimeler

pon1, Lipo(a), diabetes mellitus

Kaynakça

• 1. Berg K. A new serum type system in man the lp system. Acta Pathol Microbiol Scand. 1963;59:369-382.
• 2. Çekmen MB, TürközY, Turgut M, Gözükara EM. Lipoprotein (a): Genel Bir Bakış ve Çeşitli Hastalıklarla İlişkisi. Turgut Özal Tıp Merkezi Dergisi. 1997;4(4):462-471.
• 3. Tsimikas, S. A test in context: Lipoprotein(a): Diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692-711.
• 4. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57:1339-1359.
• 5. Leibundgut G, Scipione C, Yin H, Schneider M, et al. Tsimikas. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res. 2013;54:2815-30.
• 6. Yano Y1, Shimokawa K, Okada Y, Noma A. Immunolocalization of lipoprotein(a) in wounded tissues. Journal of Histochemistry and Cytochemistry. 1997;45:559.
• 7. Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature.1987;330:113-114.
• 8. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science.2005;309:469-472.
• 9. Byun YS, Lee JH, Arsenault BJ, et al. Investigators. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol. 2015;65:1286-1295.
• 10 . Byun YS, Yang X, Bao W, et al. Investigators. Oxidized phospholipids on apolipoprotein B-100 and recurrent ischemic events following stroke or transient ischemic attack. J Am Coll Cardiol. 2017;69:147-158.
• 11. Leibundgut G, Arai K, Orsoni A, et al. Tsimikas. Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol. 2012;59:1426-1437.
• 12. DeFilippis, AP, Chernyavskiy I, Amraotkar AR, et al. Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. J Thromb Thrombolysis. 2016;42:61-76.
• 13. Leibundgut G, Lee JH, Strauss BH, Segev A, Tsimikas S. Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina. J Thromb Thrombolysis. 2016;41:569-580.
• 14. Eliasson MC, Jansson JH, Lindahl B, Stegmayr B. High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovasc Diabetol. 2003;2:19.
• 15. Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36:2239-2245.
• 16. Apro J, Tietge U, Dikkers A, Parini P, Angelin B, Rudling M. Impaired cholesterol efflux capacity of high-density lipoprotein isolated from interstitial fluid in type 2 diabetes mellitus- brief report. Arterioscler Thromb Vasc Biol. 2016;36:787-91.
• 17. Parhofer KG. Interaction between glucose and lipidmetabolism: more than diabetic dyslipidemia. Diabetes Metab J. 2015;39:353-62.
• 18. Lund-Katz S, Phillips MC. High-density lipoprotein structure function and role in reverse cholesterol transport. Subcell Biochem. 2010;51:183-227.
• 19. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol. 2001;38:163-9.
• 20. Nobecourt E, Davies MJ, Brown BE, et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia. 2007;50:643-53.
• 21. Kunutsor SK, Kieneker LM, Bakker SJL, James RW, Dullaart RPF. Incident type 2 diabetes is associated with HDL, but not with its anti-oxidant constituent-paraoxonase-1: the prospective cohort PREVEND study. Metabolism. 2017;73:43-51.
• 22. Hedrick CC, Thorpe SR, Fu MX, et al. Glycation impairs high-density lipoprotein function. Diabetologia. 2000;43:312-20.
• 23. JangW, Jeoung NH, Cho KH. Modified apolipoprotein (apo) A-I by artificial sweetener causes severe premature cellular senescence and atherosclerosis with impairment of functional and structural properties of apoA-I in lipid-free and lipid-bound state. Mol Cells. 2011;31:461-70.
• 24. Sharif S, van der Graaf Y, Nathoe HM, de Valk HW, Visseren FLJ, Westerink J. HDL cholesterol as a residual risk factor for vascular events and all-cause mortality in patients with type 2 diabetes. Diabetes Care. 2016;39:1424-30.
• 25. Levitsky L, Scanu A, Gould SH. Lipo(a) levels in black and white children and adolescents with IDDM. Diabetes Care. 1991;14:283-87.
• 26. Bruckert E, Davidoff P, Grimaldi A, Truffert J, Giral P. Increased serum levels of lipo(a) in diabetes mellitus and their reduction with glycemic control. Jama. 1990;263:35-36.
• 27. Haffner SM, Tuttle KR, Rainwater DL. Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects. Diabetes Care. 1991;14:302-7.
• 28. Gürsu MF, Özdin M. Lipoprotein (A) düzeyleri ile paraoksonaz (PON 1) aktivitelerinin kopmlikasyonlu ve komplikasyonsuz tip 2 diyabetik (NIDDM) hastalarda araştırılması. Fırat Tıp Dergisi. 2002; 7( 2) :720-726.
• 29 . Crow JA, Meek EC, Wills RW, Chambers JE. A case-control study: The association of serum paraoxonase 1 activity and concentration with the development of type 2 diabetes mellitus. Diabetes Metab Res Rev. 2018;34(3). Doi: 10.1002/dmrr.2967.